INBX’s INBRX-106 plus pembrolizumab posts strong Phase 2 HNSCC results

Phase 2 HNSCC data show INBRX-106 plus pembrolizumab nearly doubled response rates and improved six-month progression-free survival, with especially strong results in HPV+ patients. The combination was well tolerated and will be further studied.